Vitiligo Treatment in 2025: What Has Changed and What Works

Vitiligo — the loss of skin pigmentation in patches — affects approximately 1–2% of the global population and is particularly common in India. While vitiligo is not medically dangerous, its cosmetic and psychological impact can be significant. Treatment has evolved substantially in recent years.

Understanding Vitiligo

Vitiligo is an autoimmune condition where the body's immune system attacks melanocytes (pigment-producing cells), causing white patches on the skin. It can appear at any age but typically begins before 30.

Types of vitiligo relevant to treatment:

• Non-segmental (generalized): Symmetrical patches on both sides of the body. Progressive — tends to spread over time. Responds to medical management.
• Segmental: Affects one side of the body in a dermatomal pattern. Tends to stabilize relatively quickly. Better candidate for surgical treatment.
• Focal: One or a few patches in a single area. May remain stable or evolve into generalized.

Medical Treatment (First Line)

Topical Therapies

Topical corticosteroids (potent): Still the first-line treatment for limited vitiligo. Clobetasol propionate or mometasone furoate applied to white patches for 2–3 months. Effective in 40–60% of cases, particularly on the face and neck. Must be monitored for steroid side effects (skin thinning).

Topical calcineurin inhibitors (tacrolimus 0.1%, pimecrolimus): Steroid-sparing alternatives, particularly preferred for facial vitiligo where long-term steroid use is risky. Slower onset but safer for prolonged use.

Topical JAK inhibitors (ruxolitinib cream): This is the most significant recent development. Ruxolitinib 1.5% cream (FDA-approved in 2022 for non-segmental vitiligo) directly targets the JAK-STAT signaling pathway that drives the autoimmune destruction of melanocytes. Early studies show significant repigmentation in facial vitiligo. This represents a genuine breakthrough in topical vitiligo therapy.

Phototherapy

Narrowband UVB (NB-UVB): The gold standard medical treatment for widespread vitiligo. Sessions 2–3 times per week for 6–12 months. NB-UVB stimulates melanocyte proliferation and migration from hair follicle reservoirs into the depigmented skin.

Success factors:

• Best results on face, neck, and trunk (60–70% can achieve significant repigmentation)
• Hands, feet, and bony prominences respond poorly
• Dark hair within the white patches = better prognosis (indicates surviving melanocytes in hair follicles)
• White hair within patches = poor prognosis (melanocyte reservoir is depleted)

Excimer laser (308nm): Targeted UVB delivery to individual patches. Useful when patches are few and small. Higher per-session energy than booth NB-UVB, potentially faster response. We use this at Vernon for localized patches.

Surgical Treatment

Surgical vitiligo treatment is indicated when:

1. Vitiligo has been stable (no new patches, no progression) for at least 6–12 months
2. Medical treatment has failed or is insufficient
3. The patient has segmental vitiligo (excellent surgical candidate)

Melanocyte Transfer Techniques

Suction blister grafting: Blisters are created on normally pigmented donor skin using suction. The thin epidermal roof (containing melanocytes) is transplanted to the dermabraded recipient site. Dr. Reddy has extensive experience with this technique.

Non-cultured melanocyte-keratinocyte transplant (MKTP): A small piece of donor skin is processed in a laboratory to create a cell suspension containing melanocytes and keratinocytes. This suspension is applied to the dermabraded recipient area. This technique can cover larger areas from a small donor piece — typically a 1:5 to 1:10 ratio (1 sq cm of donor treats 5–10 sq cm of vitiligo).

Punch grafting: Small 1–2mm punch grafts from pigmented skin are placed into punch holes in the vitiligo patch. Simpler technique but leaves a cobblestoned appearance that requires subsequent phototherapy to blend.

Surgical Success Factors

• Segmental vitiligo: 85–95% repigmentation success rate
• Stable non-segmental vitiligo: 60–75% success rate
• Lips: Special techniques needed — respond well to melanocyte transfer
• Fingertips/genitals: Moderate success with specific protocols

What Does NOT Work

1. Oral glutathione for vitiligo: Glutathione suppresses melanin production — the opposite of what vitiligo patients need. I see patients who have been prescribed glutathione for "skin health" while simultaneously having vitiligo. This is contradictory.

2. Ayurvedic "cures": While some herbal agents like psoralen (from Psoralea corylifolia) have legitimate photosensitizing effects used in PUVA therapy, unregulated ayurvedic formulations often contain harmful adulterants, steroids, or ineffective doses.

3. Tattoo camouflage as primary treatment: Cosmetic tattooing (micropigmentation) can provide cosmetic improvement but does not restore melanocytes. The tattooed pigment fades differently than surrounding skin, can look unnatural in changing light, and precludes future medical or surgical treatment of the area.

Realistic Expectations

Vitiligo treatment requires patience. Meaningful repigmentation takes 3–12 months of consistent therapy. Complete repigmentation of all patches is achieved in approximately 20–30% of cases with aggressive combined treatment. Most patients achieve significant improvement — enough to meaningfully improve appearance and confidence — but some residual patches may persist.

The face responds best. Hands and feet respond poorest. Hair follicle melanocytes are the reservoir for repigmentation — areas with dark hair in the patches have the best prognosis.

The Vernon Approach

At Vernon, vitiligo treatment begins with a thorough assessment:

1. Classification (segmental vs. non-segmental)
2. Stability assessment (Wood's lamp examination, photography)
3. Activity markers (confetti-like depigmentation at patch borders = active disease)
4. Treatment history review
5. Prognostic assessment (hair color within patches, body location)

Based on this assessment, we create a personalized treatment plan that may combine topical therapy, phototherapy, and/or surgical intervention — always with honest communication about expected outcomes.